mavorixafor

FDA Drug Profile — XOLREMDI

Drug Details

Generic Name
mavorixafor
Brand Names
XOLREMDI
Application Number
NDA218709
Sponsor
X4 Pharmaceuticals, Inc.
NDC Codes
1
Dosage Forms
CAPSULE, GELATIN COATED
Routes
ORAL
Active Ingredients
MAVORIXAFOR

Indications and Usage

1 INDICATIONS AND USAGE XOLREMDI is indicated in patients 12 years of age and older with WHIM syndrome (warts, hypogammaglobulinemia, infections and myelokathexis) to increase the number of circulating mature neutrophils and lympocytes. XOLREMDI is a CXC chemokine receptor 4 antagonist indicated in patients 12 years of age and older with WHIM syndrome (warts, hypogammaglobulinemia, infections and myelokathexis) to increase the number of circulating mature neutrophils and lymphocytes. ( 1 )